The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•31 March 2026•

1 min read

Tarsus Pharmaceuticals Initiates Phase 2 Trial for Lyme Disease Prevention Treatment

Key Facts

1Tarsus Pharmaceuticals announced the first participant has been dosed in the Phase 2 Calliope clinical trial of TP-05.

2TP-05 (lotilaner) is an investigational oral tablet designed to prevent Lyme disease by killing infected ticks before transmission.

3Tarsus Pharmaceuticals is traded on NASDAQ under the ticker TARS.

Create Free Account

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced the commencement of dosing in its Phase 2 Calliope clinical trial for TP-05, an investigational treatment for Lyme disease. TP-05, or lotilaner, is an oral tablet designed to prevent the disease by killing infected ticks before they can transmit the Borrelia burgdorferi bacteria. This trial marks a significant milestone in the company's clinical pipeline, focusing on systemic prevention of tick-borne illnesses. The advancement into Phase 2 is a critical step for the biotech firm, potentially increasing investor confidence in its long-term growth prospects. Market participants are closely watching the safety and efficacy data from this study as it progresses. If successful, this novel approach could establish a new standard for Lyme disease prevention. The company continues to focus on addressing high unmet medical needs through innovative pharmaceutical solutions.